Eosinophilic gastrointestinal disorders (EGID ... However, many aspects of the disease remain unknown. Thus, no definitive epidemiological features have been established, physiopathological ...

Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a study published online Nov. 27 in The ...

Patients with eosinophilic asthma tend to have more severe disease, and more frequent asthma exacerbations. In the past five years, three monoclonal antibody therapies that target interleukin-5 or ...

Incidence of eosinophilic esophagitis has increased, and it is now a highly prevalent disorder. A review of published literature shows a delay in diagnosis, a lack of standard treatments achieving ...

EsoCap, a privately funded company based in Basel, Switzerland, has come up with a novel solution to increase mucosal contact time in the upper gastrointestinal tract and esophageal drug deposition.

Detailed results of the ACESO Phase II study published in the peer-reviewed medical journal Alimentary Pharmacology & ...

In collaboration with physicians from the Division of Gastroenterology and Nutrition, allergists in the Division assist in the evaluation of patients with eosinophilic gastrointestinal diseases such ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Unspecified Respiratory Disorders.

the immune disease eosinophilic esophagitis (EoE). The trial will enroll 64 healthy volunteers, Holoclara CEO and co-founder Andrea Choe, M.D., Ph.D., told Fierce Biotech in an interview.